Risks of Iron Transfusions

Iron Overload: The Primary Long-Term Risk

Each unit of packed red blood cells contains approximately 200-250 mg of elemental iron that accumulates in the body with no active physiological excretion mechanism, according to the American Journal of Hematology 1, 2
Iron overload is the leading cause of death in transfusion-dependent patients, with heart disease accounting for approximately 70% of deaths in conditions like β-thalassemia, as reported by the American Journal of Hematology 3, 4, 2
Liver disease with fibrosis and cirrhosis occurs from iron deposition; even small amounts of iron amplify toxic effects of alcohol and viruses, rapidly accelerating fibrotic response, according to the American Journal of Hematology 3, 4
Endocrine dysfunction, including hypothyroidism and diabetes, causes considerable morbidity and mortality in chronically transfused patients, as noted by the American Journal of Hematology 3, 4
In myelodysplastic syndromes (MDS), developing secondary iron overload significantly worsens survival, with a 30% increase in hazard for every 500 ng/mL increase in serum ferritin above threshold, according to the American Journal of Hematology 3

Red blood cell transfusion in cancer patients is associated with increased risks of arterial and venous thrombosis as well as increased mortality risk, as reported by the American Journal of Hematology 6, 7
In surgical cancer patients, transfusion is independently associated with increased risk of mortality, morbidity, and cancer recurrence, according to the Annals of Oncology 8, 9
Transfusion-related immunosuppression increases risk of infections, as noted by the Annals of Oncology 8, 9
Volume overload is particularly problematic in patients with cardiac or renal dysfunction, according to the American Journal of Hematology 6, 7

The American Journal of Hematology recommends maintaining hemoglobin transfusion threshold around 7-8 g/dL in stable, non-cardiac inpatients rather than liberal thresholds 8, 9
Restrictive approaches (Hb <7 g/dL) show significant reductions in total and in-hospital mortality, rebleeding, acute coronary syndrome, edema, and bacterial infections compared to liberal strategies, as reported by the Annals of Oncology 8, 9
Patients with MDS and regular transfusion need should be considered for chelation therapy to preserve quality of life, organ function, and possibly improve survival, according to the American Journal of Hematology 3, 5, 4
Cardiac T2 MRI showing T2 <20 ms suggests cardiac iron accumulation, with T2* <6 ms conferring 47% risk of heart failure within 1 year, as noted by Praxis Medical Insights 10